Tags

Type your tag names separated by a space and hit enter

Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Clin Microbiol Infect. 2022 Apr; 28(4):596-601.CM

Abstract

OBJECTIVES

The identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen or RNA in respiratory specimens ≥14 days after administration of all recommended doses of authorized coronavirus disease 2019 (COVID-19) vaccines is defined as breakthrough infection. In the present investigation, mRNA and vector-based SARS-CoV-2 vaccines were analysed with respect to postvaccination infections in vaccinated hospital employees.

METHODS

A total of 8553 staff members were vaccinated with BNT162b2 (47%) or ChAdOx1-S (53%) between January and May 2021. In a retrospective observational cohort study, incidence of SARS-CoV-2 postvaccination infections was analysed in relation to demographic data, viral load, virus variants, vaccine brand and vaccination status at time of positive PCR test (fully vaccinated: ≥14 days since second dose; partially vaccinated: >21 days since first, but <14 days after second dose; insufficiently vaccinated: <22 days since first dose).

RESULTS

Within the follow-up period, ending on 31 July 2021, person-time at risk-adjusted monthly rates for SARS-CoV-2 postvaccination infections were 0.18% (BNT162b2) and 0.57% (ChAdOx1-S) for insufficiently vaccinated, 0.34% (BNT162b2) and 0.32% (ChAdOx1-S) for partially vaccinated and 0.06% (BNT162b2) and 0.04% (ChAdOx1-S) for fully vaccinated participants. The two vaccine types did not differ with respect to hazard ratios for any of the respective postvaccination infection types. No cases of COVID-19-related hospitalizations or deaths were reported. Genotyping of positive PCR specimens revealed 42 variants of concern: B.1.1.7 (Alpha variant; n = 34); B.1.351 (Beta variant; n = 2), B.1.617.2 (Delta variant; n = 6).

CONCLUSIONS

BNT162b2 and ChAdOx1-S are both effective in preventing breakthrough infections; however, it seems important, that all recommended vaccine doses are administered.

Links

PMC Free PDF

Authors+Show Affiliations

Brunner-Ziegler S
Department of Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria. Electronic address: sophie.brunner-ziegler@meduniwien.ac.at.
Spath T
Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.
Kornek G
Medical Directorate, Vienna General Hospital, Vienna, Austria.
König F
Centre for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
Parschalk B
Department of Ear, Nose and Throat Diseases, Medical University of Vienna, Vienna, Austria.
Schnetzinger M
Department of Anaesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria.
Straβl RP
Division of Clinical Virology, Medical University of Vienna, Vienna, Austria.
Savic R
Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.
Foit A
Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.
Resch H
Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.
Thalhammer F
Department of Urology, Medical University of Vienna, Vienna, Austria.

MeSH

BNT162 VaccineCOVID-19COVID-19 VaccinesHumansRNA, MessengerRetrospective StudiesSARS-CoV-2Tertiary Care CentersVaccinationmRNA Vaccines

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

34915073

Citation

Brunner-Ziegler, Sophie, et al. "Postvaccination Infections Among Staff of a Tertiary Care Hospital After Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Vector and mRNA-based Vaccines." Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 28, no. 4, 2022, pp. 596-601.
Brunner-Ziegler S, Spath T, Kornek G, et al. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clin Microbiol Infect. 2022;28(4):596-601.
Brunner-Ziegler, S., Spath, T., Kornek, G., König, F., Parschalk, B., Schnetzinger, M., Straβl, R. P., Savic, R., Foit, A., Resch, H., & Thalhammer, F. (2022). Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 28(4), 596-601. https://doi.org/10.1016/j.cmi.2021.11.023
Brunner-Ziegler S, et al. Postvaccination Infections Among Staff of a Tertiary Care Hospital After Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Vector and mRNA-based Vaccines. Clin Microbiol Infect. 2022;28(4):596-601. PubMed PMID: 34915073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines. AU - Brunner-Ziegler,Sophie, AU - Spath,Tibor, AU - Kornek,Gabriela, AU - König,Franz, AU - Parschalk,Bernhard, AU - Schnetzinger,Maximilian, AU - Straβl,Robert Paul, AU - Savic,Rebeka, AU - Foit,Andrea, AU - Resch,Helene, AU - Thalhammer,Florian, Y1 - 2021/12/13/ PY - 2021/09/04/received PY - 2021/11/16/revised PY - 2021/11/25/accepted PY - 2021/12/17/pubmed PY - 2022/4/6/medline PY - 2021/12/16/entrez KW - Breakthrough infection KW - Hospital employees KW - Postvaccination infection KW - Severe acute respiratory syndrome coronavirus 2 KW - Vector-based vaccine KW - mRNA-based vaccine SP - 596 EP - 601 JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JO - Clin Microbiol Infect VL - 28 IS - 4 N2 - OBJECTIVES: The identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen or RNA in respiratory specimens ≥14 days after administration of all recommended doses of authorized coronavirus disease 2019 (COVID-19) vaccines is defined as breakthrough infection. In the present investigation, mRNA and vector-based SARS-CoV-2 vaccines were analysed with respect to postvaccination infections in vaccinated hospital employees. METHODS: A total of 8553 staff members were vaccinated with BNT162b2 (47%) or ChAdOx1-S (53%) between January and May 2021. In a retrospective observational cohort study, incidence of SARS-CoV-2 postvaccination infections was analysed in relation to demographic data, viral load, virus variants, vaccine brand and vaccination status at time of positive PCR test (fully vaccinated: ≥14 days since second dose; partially vaccinated: >21 days since first, but <14 days after second dose; insufficiently vaccinated: <22 days since first dose). RESULTS: Within the follow-up period, ending on 31 July 2021, person-time at risk-adjusted monthly rates for SARS-CoV-2 postvaccination infections were 0.18% (BNT162b2) and 0.57% (ChAdOx1-S) for insufficiently vaccinated, 0.34% (BNT162b2) and 0.32% (ChAdOx1-S) for partially vaccinated and 0.06% (BNT162b2) and 0.04% (ChAdOx1-S) for fully vaccinated participants. The two vaccine types did not differ with respect to hazard ratios for any of the respective postvaccination infection types. No cases of COVID-19-related hospitalizations or deaths were reported. Genotyping of positive PCR specimens revealed 42 variants of concern: B.1.1.7 (Alpha variant; n = 34); B.1.351 (Beta variant; n = 2), B.1.617.2 (Delta variant; n = 6). CONCLUSIONS: BNT162b2 and ChAdOx1-S are both effective in preventing breakthrough infections; however, it seems important, that all recommended vaccine doses are administered. SN - 1469-0691 UR - https://www.unboundmedicine.com/medline/citation/34915073/Postvaccination_infections_among_staff_of_a_tertiary_care_hospital_after_vaccination_with_severe_acute_respiratory_syndrome_coronavirus_2_vector_and_mRNA_based_vaccines_ DB - PRIME DP - Unbound Medicine ER -